Persistence of nevirapine in breast milk after discontinuation of treatment.
The objective of this study was to serially quantitate the concentration of nevirapine in breast milk after discontinuation of treatment. Samples were collected from both breasts of a human immunodeficiency virus-infected patient for 3 weeks. Nevirapine was quantifiable for up to 17 days after discontinuation of therapy; total nevirapine concentrations remained above the 90% inhibitory concentration for 6 days, and no differences were observed between breasts.
Bennetto-Hood
Chantelle
C
Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294-0019, USA.
Aldrovandi
Grace M
GM
King
Jennifer R
JR
Woodman
Kyra
K
Ashouri
Negar
N
Acosta
Edward P
EP
D019380:Anti-HIV Agents / Q000302:isolation & purification* / Q000627:therapeutic use; D005260:Female; D007839:Functional Laterality; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008895:Milk, Human / Q000737:chemistry*; D019829:Nevirapine / Q000302:isolation & purification* / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000821:virology
D019380:Anti-HIV Agents; D019829:Nevirapine